Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China

View Full Paper
Ask AI
Bookmark
Share

Authors

WSWei SuJHJianhua Han

Discussion

Loading...

Member takes

Overview

Mass spectrometry screening identified 201 monoclonal gammopathy cases, highlighting its advantages in clinical monitoring and risk stratification.

Key Points

  • Monoclonal gammopathy screening via mass spectrometry detected over 130 additional cases compared to conventional methods.
  • This analysis of 15,068 samples shows a significant superiority of mass spectrometry in identifying true monoclonal gammopathy cases.
  • Assessment used a novel iMS-LC Assay, outperforming standard serum protein electrophoresis in sensitivity and detection rates.
  • Highlights the potential for mass spectrometry to enable earlier identification and management of monoclonal gammopathies in populations.

Cite This Study

Su et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e033https://doi.org/10.1182/blood-2025-5744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL2025
  2. 2Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial2025
  3. 3Clinical applications of mass spectrometry in multiple myeloma2025 · 8 citations
  4. 4B-348 M protein cut-off for initial evaluation of monoclonal gammopathies with the Immunglobulin Isotypes (GAM) for the EXENT® analyzer MALDI-ToF assay2025
  5. 5Laboratory characteristics of monoclonal gammopathy of undetermined significance (MGUS) in a diverse sample from three large cancer epidemiology cohorts.2025